Johnson & Johnson vs Eli Lilly (JNJ vs LLY)
Johnson & Johnson (JNJ) trades at $270.47 and Eli Lilly (LLY) at $1,347.11. Eli Lilly is the larger company ($1.1T vs $683B). ATLAS gives Johnson & Johnson the higher odds of rising next month (52% vs 51%). Against ATLAS fair value, Johnson & Johnson is 35% above fair value and Eli Lilly is 63% above fair value.
Updated Nov 20, 2026. Educational information, not investment advice.
A side-by-side comparison of Johnson & Johnson (JNJ) and Eli Lilly (LLY) — valuation, dividend, growth and the ATLAS model's odds for each. Figures are the same ATLAS shows on each stock's page.
| JNJ Johnson & Johnson | LLY Eli Lilly | |
|---|---|---|
| Price | $270.47 | $1,347.11 |
| Market caplarger company | $683B | $1.1T✓ |
| P/E ratiocheaper per $1 of earnings | 41.1✓ | 43.7 |
| ATLAS odds it rises (next month)model's probability of closing higher in ~21 sessions | 52% | 51% |
| Vs ATLAS fair valuebigger discount to fair value | 35% above fair value✓ | 63% above fair value |
| Dividend yieldpays more income | 1.95%✓ | 0.51% |
| Revenue growth (YoY)growing faster | +6.0% | +44.7%✓ |
| Net marginmore profitable | 28.5% | 31.7%✓ |
| 1-year returnstronger past year | +32.6%✓ | +27.1% |
A ✓ marks the stronger value on that single metric — it is not a recommendation. Prices are in each company’s listing currency; market cap is in USD.
JNJ vs LLY — common questions
Is Johnson & Johnson or Eli Lilly cheaper?
On earnings, Johnson & Johnson is cheaper: a P/E of 41.1 versus 43.7. Against ATLAS fair value, Johnson & Johnson is 35% above fair value and Eli Lilly is 63% above fair value.
Does Johnson & Johnson or Eli Lilly have higher upside according to ATLAS?
ATLAS gives Johnson & Johnson the higher probability of closing higher over the next month: 52% versus 51%.
Which pays a bigger dividend, Johnson & Johnson or Eli Lilly?
Johnson & Johnson has the higher dividend yield: 1.95% versus 0.51%.
Is Johnson & Johnson bigger than Eli Lilly?
No — Eli Lilly is the larger company by market value: $1.1T versus $683B.
Which is growing faster, Johnson & Johnson or Eli Lilly?
Eli Lilly grew revenue faster over the last year: +44.7% versus +6.0% year over year.
Follow both on ATLAS — probability, fair value and earnings for JNJ, LLY and 50,000+ more.
Open ATLAS free →ATLAS is educational information, not investment advice. Figures update roughly every few hours.